Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Monson Jonathan

2. Date of Event Requiring Statement (MM/DD/YYYY) 7/1/2019

3. Issuer Name and Ticker or Trading Symbol

BOSTON SCIENTIFIC CORP [BSX]

(Last) (First) (Middle)

300 BOSTON SCIENTIFIC WAY

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
VP, Corp Controller and CAO /

(Street)

MARLBOROUGH, MA 01752-1234

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	29599.0000	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Deferred Stock Units	⁽¹⁾	2/15/2023 ⁽¹⁾	Common Stock	2953.0000 ⁽²⁾	⁽³⁾	D
Deferred Stock Units	⁽⁴⁾	2/21/2023 ⁽⁴⁾	Common Stock	2492.0000	⁽³⁾	D
Deferred Stock Units	⁽⁵⁾	2/22/2021 ⁽⁵⁾	Common Stock	2318.0000 ⁽⁶⁾	⁽³⁾	D
Deferred Stock Units	⁽⁷⁾	2/28/2022 ⁽⁷⁾	Common Stock	2445.0000 ⁽⁸⁾	⁽³⁾	D
Deferred Stock Units	⁽⁹⁾	12/1/2019 ⁽⁹⁾	Common Stock	2910.0000 ⁽¹⁰⁾	⁽³⁾	D
Stock Option (Right to Buy)	⁽¹¹⁾	12/1/2024	Common Stock	17901.0000	$12.8900	D
Stock Option (Right to Buy)	⁽¹²⁾	2/24/2024	Common Stock	5000.0000	$13.0800	D
Stock Option (Right to Buy)	⁽¹³⁾	2/22/2026	Common Stock	18450.0000	$17.2600	D
Stock Option (Right to Buy)	⁽¹⁴⁾	2/28/2027	Common Stock	14430.0000	$24.5500	D
Stock Option (Right to Buy)	⁽¹⁵⁾	2/15/2028	Common Stock	12004.0000	$27.0900	D
Stock Option (Right to Buy)	⁽¹⁶⁾	2/21/2029	Common Stock	8605.0000	$40.1200	D

Explanation of Responses:
(1)	Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
(2)	This amount represents the unvested portion of DSUs awarded on February 15, 2018, which will continue to vest in four remaining installments on the anniversary of the date of grant.
(3)	Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
(4)	Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.
(5)	Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
(6)	This amount represents the unvested portion of DSUs awarded on February 22, 2016, which will continue to vest in two remaining installments on the anniversary of the date of grant.
(7)	Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
(8)	This amount represents the unvested portion of DSUs awarded on February 28, 2017, which will continue to vest in three remaining installments on the anniversary of the date of grant.
(9)	Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant.
(10)	This amount represents the unvested portion of DSUs awarded on December 1, 2014, which will continue to vest in one remaining installment on the anniversary of the date of grant.
(11)	Grant to the reporting person on December 1, 2014, of an option to purchase 17,901 shares of common stock. This grant is fully vested.
(12)	Grant to the reporting person on February 24, 2014, of an option to purchase 15,000 shares of common stock. This grant is fully vested.
(13)	Grant to the reporting person of an option to purchase 18,450 shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant.
(14)	Grant to the reporting person of an option to purchase 14,430 shares of common stock vesting in four equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant.
(15)	Grant to the reporting person of an option to purchase 12,004 shares of common stock vesting in four equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant.
(16)	Grant to the reporting person of an option to purchase 8,605 shares of common stock vesting in four equal annual installments beginning on February 21, 2020, the first anniversary of the date of grant.

Remarks:
monsonpoa.txt

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Monson Jonathan 300 BOSTON SCIENTIFIC WAY MARLBOROUGH, MA 01752-1234			VP, Corp Controller and CAO

Signatures
/s/ Scott G. Hodgdon, Attorney-in-Fact		7/1/2019
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.